1. Home
  2. TNXP vs NEPH Comparison

TNXP vs NEPH Comparison

Compare TNXP & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • NEPH
  • Stock Information
  • Founded
  • TNXP 2007
  • NEPH 1997
  • Country
  • TNXP United States
  • NEPH United States
  • Employees
  • TNXP N/A
  • NEPH N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • NEPH Medical/Dental Instruments
  • Sector
  • TNXP Health Care
  • NEPH Health Care
  • Exchange
  • TNXP Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • TNXP 19.5M
  • NEPH 15.9M
  • IPO Year
  • TNXP N/A
  • NEPH 2004
  • Fundamental
  • Price
  • TNXP $0.61
  • NEPH $1.54
  • Analyst Decision
  • TNXP Strong Buy
  • NEPH Buy
  • Analyst Count
  • TNXP 2
  • NEPH 1
  • Target Price
  • TNXP $53.50
  • NEPH $5.00
  • AVG Volume (30 Days)
  • TNXP 202.6M
  • NEPH 9.8K
  • Earning Date
  • TNXP 11-12-2024
  • NEPH 11-07-2024
  • Dividend Yield
  • TNXP N/A
  • NEPH N/A
  • EPS Growth
  • TNXP N/A
  • NEPH N/A
  • EPS
  • TNXP N/A
  • NEPH N/A
  • Revenue
  • TNXP $11,291,000.00
  • NEPH $13,546,000.00
  • Revenue This Year
  • TNXP $64.71
  • NEPH N/A
  • Revenue Next Year
  • TNXP $24.49
  • NEPH $9.13
  • P/E Ratio
  • TNXP N/A
  • NEPH N/A
  • Revenue Growth
  • TNXP 183.05
  • NEPH 0.03
  • 52 Week Low
  • TNXP $0.12
  • NEPH $1.36
  • 52 Week High
  • TNXP $14.08
  • NEPH $4.04
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 75.02
  • NEPH 47.64
  • Support Level
  • TNXP $0.32
  • NEPH $1.53
  • Resistance Level
  • TNXP $0.72
  • NEPH $1.64
  • Average True Range (ATR)
  • TNXP 0.15
  • NEPH 0.06
  • MACD
  • TNXP 0.04
  • NEPH -0.01
  • Stochastic Oscillator
  • TNXP 39.61
  • NEPH 37.50

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.

Share on Social Networks: